{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:14:25Z","timestamp":1789820065151,"version":"4.0.1"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:p>Background. Available therapeutic surfactants are either animal-derived or non\u2013protein-containing synthetic products. Animal-derived surfactants contain variable amounts of surfactant apoproteins, whereas the older-generation synthetic products contain only phospholipids and lack surfactant proteins (SPs). Both decrease morbidity and mortality rates associated with respiratory distress syndrome (RDS) among preterm infants, compared with placebo. However, excess mortality rates have been observed with non\u2013protein-containing synthetic surfactants, compared with the animal-derived products. Evidence suggests that synthetic surfactants consisting solely of phospholipids can be improved with the addition of peptides that are functional analogs of SPs. Lucinactant is a new synthetic peptide-containing surfactant that contains sinapultide, a novel, 21-amino acid peptide (leucine and lysine repeating units, KL4 peptide) designed to mimic human SP-B. It is completely devoid of animal-derived components.<\/jats:p><jats:p>Objective. We hypothesized that the outcomes for premature infants treated with lucinactant and poractant alfa would be similar. Therefore, we compared lucinactant (Surfaxin; Discovery Laboratories, Doylestown, PA) with porcine-derived, poractant alfa (Curosurf; Chiesi Farmaceutici, Parma, Italy) in a trial to test for noninferiority.<\/jats:p><jats:p>Methods. A total of 252 infants born between 24 and 28 weeks of completed gestation, with birth weights between 600 and 1250 g, were assigned randomly in a multicenter, multinational, noninferiority, randomized, controlled study to receive either lucinactant (n = 124) or poractant alfa (n = 128) within 30 minutes of life. The primary outcome was the incidence of being alive without bronchopulmonary dysplasia (BPD) through 28 days of age. Key secondary outcomes included death at day 28 and 36 weeks postmenstrual age (PMA), air leaks, neuroimaging abnormalities, and other complications related to either prematurity or RDS. An independent, international, data and safety monitoring committee monitored the trial.<\/jats:p><jats:p>Results. The treatment difference between lucinactant and poractant alfa for survival without BPD through 28 days was 4.75% (95% confidence interval [CI]: \u22127.3% to 16.8%) in favor of lucinactant, with the lower boundary of the 95% CI for the difference, ie, \u22127.3%, being greater than the prespecified noninferiority margin of \u221214.5%. At 28 days, 45 of 119 infants given lucinactant were alive without BPD (37.8%; 95% CI: 29.1\u201346.5%), compared with 41 of 124 given poractant alfa (33.1%; 95% CI: 24.8\u201341.3%); at 36 weeks PMA, the rates were 64.7% and 66.9%, respectively. The corresponding mortality rate through day 28 for the lucinactant group was lower than that for the poractant alfa group (11.8% [95% CI: 6.0\u201317.6%] vs 16.1% [95% CI: 9.7\u201322.6%]), as was the rate at 36 weeks PMA (16% and 18.5%, respectively). There were no differences in major dosing complications. In addition, no significant differences were observed in the incidences of common complications of prematurity, including intraventricular hemorrhage (grades 3 and 4) and cystic periventricular leukomalacia (lucinactant: 14.3%; poractant alfa: 16.9%).<\/jats:p><jats:p>Conclusions. Lucinactant and poractant alfa were similar in terms of efficacy and safety when used for the prevention and treatment of RDS among preterm infants. The ability to enhance the performance of a synthetic surfactant with the addition of a peptide that mimics the action of SP-B, such as sinapultide, brings potential advantages to exogenous surfactant therapy.<\/jats:p>","DOI":"10.1542\/peds.2004-2231","type":"journal-article","created":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T18:03:40Z","timestamp":1112378620000},"page":"1030-1038","source":"Crossref","is-referenced-by-count":162,"title":["A Multicenter, Randomized, Controlled Trial of Lucinactant Versus Poractant Alfa Among Very Premature Infants at High Risk for Respiratory Distress Syndrome"],"prefix":"10.1542","volume":"115","author":[{"given":"Sunil K.","family":"Sinha","sequence":"first","affiliation":[{"name":"James Cook University Hospital, Middlesbrough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Lacaze-Masmonteil","sequence":"additional","affiliation":[{"name":"Hospital Antoine-Beclere, AP\/HP, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolf","family":"Valls i Soler","sequence":"additional","affiliation":[{"name":"Hospital de Cruces, University of Basque Country, Barakaldo, Bilbao (Bizkaia), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Wiswell","sequence":"additional","affiliation":[{"name":"State University of New York, Stony Brook, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Gadzinowski","sequence":"additional","affiliation":[{"name":"Poznan University of Medical Sciences, Poznan, Poland, and Polish Mother's Memorial Hospital Research Institute, Lo\u0301dz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Hajdu","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Sharp Mary Birch Hospital for Women, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Sanchez-Luna","sequence":"additional","affiliation":[{"name":"Hospital General Gregorio Maran\u0303on, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Segal","sequence":"additional","affiliation":[{"name":"Discovery Laboratories, Inc, Doylestown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Schaber","sequence":"additional","affiliation":[{"name":"Discovery Laboratories, Inc, Doylestown, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Massaro","sequence":"additional","affiliation":[{"name":"Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"d'Agostino","sequence":"additional","affiliation":[{"name":"Boston University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Surfaxin Therapy Against Respiratory Distress Syndrome Collaborative Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2005,4,1]]},"reference":[{"key":"2021120819301716400_R1","doi-asserted-by":"crossref","unstructured":"Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev.\u20081998;(2):CD001079","DOI":"10.1002\/14651858.CD001079"},{"key":"2021120819301716400_R2","doi-asserted-by":"crossref","unstructured":"Soll RF. Prophylactic natural surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev.\u20081997;(4):CD000511","DOI":"10.1002\/14651858.CD000511"},{"key":"2021120819301716400_R3","doi-asserted-by":"crossref","unstructured":"Suresh GK, Soll RF. Lung surfactants for neonatal respiratory distress syndrome: animal-derived or synthetic agents?Paediatr Drugs.\u20082002;4:485\u2013489","DOI":"10.2165\/00128072-200204080-00001"},{"key":"2021120819301716400_R4","doi-asserted-by":"crossref","unstructured":"Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev.\u20082001;(2):CD000144","DOI":"10.1002\/14651858.CD000144"},{"key":"2021120819301716400_R5","doi-asserted-by":"crossref","unstructured":"Ainsworth SB, Beresford MW, Milligan DWA, et al. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25\u201329 weeks' gestation: a randomised trial. Lancet.\u20082000;355:1387\u20131392","DOI":"10.1016\/S0140-6736(00)02136-X"},{"key":"2021120819301716400_R6","doi-asserted-by":"crossref","unstructured":"Curstedt T, Jornvall H, Robertson B, et al. Two hydrophobic, low-molecular mass protein fractions of pulmonary surfactant: characterization and biophysical activity. Eur J Biochem.\u20081987;168:255\u2013262","DOI":"10.1111\/j.1432-1033.1987.tb13414.x"},{"key":"2021120819301716400_R7","doi-asserted-by":"crossref","unstructured":"Clark JC, Wert S, Bachurski CJ, et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc Natl Acad Sci USA.\u20081995;92:7794\u20137798","DOI":"10.1073\/pnas.92.17.7794"},{"key":"2021120819301716400_R8","doi-asserted-by":"crossref","unstructured":"Hamvas A, Nogee LM, Mallory GB Jr, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr.\u20081997;130:231\u2013239","DOI":"10.1016\/S0022-3476(97)70348-2"},{"key":"2021120819301716400_R9","doi-asserted-by":"crossref","unstructured":"Cole F, Hamvas A, Nogee LM. Genetic disorders of neonatal respiratory function. Pediatr Res.\u20082001;50:157\u2013162","DOI":"10.1203\/00006450-200108000-00001"},{"key":"2021120819301716400_R10","doi-asserted-by":"crossref","unstructured":"Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med.\u20081993;328:406\u2013410","DOI":"10.1056\/NEJM199302113280606"},{"key":"2021120819301716400_R11","doi-asserted-by":"crossref","unstructured":"Strayer DS, Hallman M, Merritt TA. Immunogenicity of surfactant. II. Porcine and bovine surfactants. Clin Exp Immunol.\u20081991;83:41\u201346","DOI":"10.1111\/j.1365-2249.1991.tb05585.x"},{"key":"2021120819301716400_R12","doi-asserted-by":"crossref","unstructured":"Robertson B, Kobayashi T, Ganzuka M, Grossmann G, Li WZ, Suzuki Y. Experimental neonatal respiratory failure induced by a monoclonal antibody to the hydrophobic surfactant-associated protein SP-B. Pediatr Res.\u20081991;30:239\u2013243","DOI":"10.1203\/00006450-199109000-00007"},{"key":"2021120819301716400_R13","doi-asserted-by":"crossref","unstructured":"Kobayashi T, Robertson B, Grossmann G, Nitta K, Curstedt T, Suzuki Y. Exogenous porcine surfactant (Curosurf) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B. Acta Paediatr.\u20081992;81:665\u2013671","DOI":"10.1111\/j.1651-2227.1992.tb12329.x"},{"key":"2021120819301716400_R14","doi-asserted-by":"crossref","unstructured":"Whitsett JA, Hull WM, Luse S. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics.\u20081997;87:505\u2013510","DOI":"10.1542\/peds.87.4.505"},{"key":"2021120819301716400_R15","doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science.\u20081991;254:566\u2013568","DOI":"10.1126\/science.1948032"},{"key":"2021120819301716400_R16","doi-asserted-by":"crossref","unstructured":"Cochrane CG. Surfactant protein B and mimic peptides in the function of pulmonary surfactant. FEBS Lett.\u20081998;430:424\u2013425","DOI":"10.1016\/S0014-5793(98)00710-8"},{"key":"2021120819301716400_R17","doi-asserted-by":"crossref","unstructured":"Revak SD, Merritt TA, Cochrane CG, et al. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr Res.\u20081996;39:715\u2013724","DOI":"10.1203\/00006450-199604000-00025"},{"key":"2021120819301716400_R18","doi-asserted-by":"crossref","unstructured":"Cochrane CG, Revak SD, Merritt TA, et al. The efficacy and safety of KL4-surfactant in preterm infants with respiratory distress syndrome. Am J Respir Crit Care Med.\u20081996;153:404\u2013410","DOI":"10.1164\/ajrccm.153.1.8542150"},{"key":"2021120819301716400_R19","doi-asserted-by":"crossref","unstructured":"Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child.\u20081993;69:276\u2013280","DOI":"10.1136\/adc.69.3_Spec_No.276"},{"key":"2021120819301716400_R20","unstructured":"Food and Drug Administration. E9 statistical principles for clinical trials. Fed Regist.\u20081998;63:49590\u201349598"},{"key":"2021120819301716400_R21","doi-asserted-by":"crossref","unstructured":"Collaborative European Multicenter Study Group. Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial. Pediatrics.\u20081988;82:683\u2013691","DOI":"10.1542\/peds.82.5.683"},{"key":"2021120819301716400_R22","doi-asserted-by":"crossref","unstructured":"Hudak ML, Martin DJ, Egan EA, et al. A multicenter randomized masked comparison trial of synthetic surfactant versus calf lung surfactant extract in the prevention of neonatal respiratory distress syndrome. Pediatrics.\u20081997;100:39\u201350","DOI":"10.1542\/peds.100.1.39"},{"key":"2021120819301716400_R23","doi-asserted-by":"crossref","unstructured":"Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev.\u20082001;(2):CD000510","DOI":"10.1002\/14651858.CD000510"},{"key":"2021120819301716400_R24","doi-asserted-by":"crossref","unstructured":"Johansson J, Curstedt T, Robertson B. Artificial surfactants based on analogues of SP-B and SP-C. Pediatr Pathol Mol Med.\u20082001;20:501\u2013518","DOI":"10.1080\/pdp.20.6.501.518"},{"key":"2021120819301716400_R25","doi-asserted-by":"crossref","unstructured":"Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child.\u20081993;69:276\u2013280","DOI":"10.1136\/adc.69.3_Spec_No.276"},{"key":"2021120819301716400_R26","doi-asserted-by":"crossref","unstructured":"Gilliard N, Richman PM, Merritt TA, Spragg RG. Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury. Am Rev Respir Dis.\u20081990;141:743\u2013747","DOI":"10.1164\/ajrccm\/141.3.743"},{"key":"2021120819301716400_R27","doi-asserted-by":"crossref","unstructured":"Van der Bleek J, Plotz FB, van Overbeek FM, et al. Distribution of exogenous surfactant in rabbits with severe respiratory failure: the effect of volume. Pediatr Res.\u20081993;34:154\u2013158","DOI":"10.1203\/00006450-199308000-00009"},{"key":"2021120819301716400_R28","doi-asserted-by":"crossref","unstructured":"Pocock SJ. The pros and cons of non-inferiority trails. Fundam Clin Pharmacol.\u20082003;17:483\u2013490.","DOI":"10.1046\/j.1472-8206.2003.00162.x"},{"key":"2021120819301716400_R29","doi-asserted-by":"crossref","unstructured":"Gomberg-Maitland M, Frison L, Haperin JL. Active-control clinical trials to establish equivalence or non-inferiority: methodological and statistical concepts linked to quality. Am Heart J.\u20082003;145:398\u2013403","DOI":"10.1016\/S0002-8703(03)00324-7"},{"key":"2021120819301716400_R30","doi-asserted-by":"crossref","unstructured":"Tsong Y, Wang SJ, Hung HM, Cui L. Statistical issues on objective, design and analysis of non-inferiority active-controlled clinical trial. J Biopharm Stat.\u20082003;13:29\u201341","DOI":"10.1081\/BIP-120017724"},{"key":"2021120819301716400_R31","doi-asserted-by":"crossref","unstructured":"Wang SJ, Hung HM. Assessing treatment efficacy in non-inferiority trials. Control Clin Trials.\u20082003;24:147\u2013155","DOI":"10.1016\/S0197-2456(02)00304-5"},{"key":"2021120819301716400_R32","doi-asserted-by":"crossref","unstructured":"Manalo E, Merritt TA, Kheiter A, Amirkhanian J, Cochrane C. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4. Pediatr Res.\u20081996;39:947\u2013952","DOI":"10.1203\/00006450-199606000-00004"},{"key":"2021120819301716400_R33","doi-asserted-by":"crossref","unstructured":"Herting E, Rauprich P, Stichtenoth G, Walter G, Johansson J, Robertson B. Resistance of different surfactant preparations to inactivation by meconium. Pediatr Res.\u20082001;50:44\u201349","DOI":"10.1203\/00006450-200107000-00010"},{"key":"2021120819301716400_R34","unstructured":"Nutt M, Patel N, Rairkar M, Niven RW. Comparison of the novel lung surfactant Surfaxin (lucinactant) with currently available commercial products. Pediatr Res.\u20082004;55:514A"},{"key":"2021120819301716400_R35","doi-asserted-by":"crossref","unstructured":"Manalo E, Merritt TA, Amirkhanian JD, Kheiter A. Characterization of surfactant subtypes of beractant and a synthetic peptide containing surfactant KL4 following surface area cycling and addition of fibrinogen. Lung.\u20081997;175:225\u2013233","DOI":"10.1007\/PL00007569"},{"key":"2021120819301716400_R36","doi-asserted-by":"crossref","unstructured":"Wiswell TE, Knight GR, Finer NN, et al. A multicenter randomized controlled trial comparing Surfaxin (lucinactant) lavage with standard of care for treatment of meconium aspiration syndrome. Pediatrics.\u20082002;109:1081\u20131087","DOI":"10.1542\/peds.109.6.1081"},{"key":"2021120819301716400_R37","doi-asserted-by":"crossref","unstructured":"Wiswell TE, Smith RM, Katz LB, et al. Bronchopulmonary segmental lavage with Surfaxin (KL4-surfactant) for acute respiratory distress syndrome. Am J Respir Crit Care Med.\u20081990;160:1188\u20131195","DOI":"10.1164\/ajrccm.160.4.9808118"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/4\/1030\/1176410\/zpe00405001030.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/115\/4\/1030\/1176410\/zpe00405001030.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T19:55:57Z","timestamp":1683057357000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/115\/4\/1030\/67636\/A-Multicenter-Randomized-Controlled-Trial-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2005,4,1]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2004-2231","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,4,1]]}}}